Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial

To the best of our knowledge, this is one of very few reports on long-term survival after trimodality therapy for locally advanced stage IIIB NSCLC. It demonstrates that selected patients can be cured by such an intensive treatment. Extended follow-up beyond 5 years, including chest imaging and opti...

Full description

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 27; no. 10; pp. 1971 - 1973
Main Authors Früh, M., Ris, H.B., Xyrafas, A., Peters, S., Mirimanoff, R.O., Gautschi, O., Pless, M., Stupp, R.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.10.2016
Subjects
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - therapy
Chemoradiotherapy - methods
Cisplatin - administration & dosage
Docetaxel
Follow-Up Studies
Humans
Lung Neoplasms - mortality
Lung Neoplasms - therapy
Neoplasm Recurrence, Local - mortality
Neoplasm Recurrence, Local - therapy
Neoplasm Staging - methods
Preoperative Care - methods
Switzerland - epidemiology
Taxoids - administration & dosage
Time Factors
Online AccessGet full text

Cover

More Information
Summary:To the best of our knowledge, this is one of very few reports on long-term survival after trimodality therapy for locally advanced stage IIIB NSCLC. It demonstrates that selected patients can be cured by such an intensive treatment. Extended follow-up beyond 5 years, including chest imaging and optimal control of cardiovascular risk factors should be integrated in future clinical trials.
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Feature-1
ObjectType-Correspondence-3
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdw251